natgillin/translations-raw huggingface dataset:
For prevention of migraine in adults, the Committee recommended a total daily dose of 100 mg, divided into two doses.
Za preprečevanje migrene pri odraslih bolnikih je Odbor priporočil skupni dnevni odmerek 100 mg, razdeljen na dva odmerka.
On 8 May 2008, the European Commission referred the matter to the CHMP in order to harmonise the marketing authorisations for Topamax and associated names in the EU and the EEA.
Da bi Evropska komisija uskladila dovoljenja za promet z zdravilom Topamax in z njim povezanimi imeni v EU in EGP, je dne 8. maja 2008 zadevo napotila na CHMP.
For adjunctive therapy, the Committee endorsed a dose range for adults of 200 to 400 mg a day, divided into two doses.
Za dodatno terapijo pri odraslih bolnikih je Odbor odobril razpon odmerkov od 200 do 400 mg na dan, razdeljenih na dva odmerka.
Topamax has been identified as needing harmonisation by the Co-ordination Group on the Mutual Recognition and Decentralised Procedures - Human (CMD(h)).
Usklajevalna skupina za postopek medsebojnega priznavanja in decentralizirane postopke za zdravila za uporabo v humani medicini (CMD(h)) je ugotovila, da je za zdravilo Topamax potrebno usklajevanje.
Advice was included in section 4.6 of the SPC about the risks to the mother and the unborn baby of treatment with Topamax.
Opozorilo o tveganju uporabe zdravila Topamax za mater in nerojenega otroka je bilo vključeno v poglavje 4.6 povzetka glavnih značilnosti zdravila.
Patients who may be hypersensitive (allergic) to the active substance or to any of the other ingredients should not take Topamax.
CHMP je odobril tudi usklajeno besedilo kontraindikacij: Zdravila Topamax ne smejo jemati bolniki, ki utegnejo biti preobčutljivi za (alergični na) zdravilno učinkovino ali katerokoli drugo sestavino zdravila.
It is used in patients who have not been treated for this disease before.
Uporablja se pri bolnikih, ki se še niso zdravili zaradi te bolezni.
In all studies, the main measure of effectiveness was the number of patients with a complete or partial response to treatment.
V vseh raziskavah je bilo glavno merilo učinkovitosti število bolnikov s popolnim ali delnim odzivom na zdravljenje.
After 14 days of treatment, both medicines had been successful in curing or improving about 92% of patients.
Po 14 dneh zdravljenja sta bili obe zdravili uspešni pri ozdravljenju ali izboljšanju stanja 92 % bolnikov.
The duration of treatment depends on the patient's condition.
Trajanje zdravljenja je odvisno od bolnikovega stanja.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil opravljene raziskave, na podlagi česar je oblikoval priporočila glede uporabe zdravila.
The most commonly reported side effects are nausea (feeling sick, 6%) and headache (6%).
Najpogostejša neželena učinka, o katerih so poročali, sta navzeja (slabost, 6 %) in glavobol (6 %).
The duration of treatment depends on the severity of the disease and the patient's response.
Trajanje zdravljenja je odvisno od resnosti bolezni in bolnikovega odziva.
If you need more information about your medical condition or your treatment, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Če potrebujete več informacij o vašem zdravstvenem stanju ali zdravljenju, preberite Navodila za uporabo (ki so prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
The effectiveness was measured by looking at how many patients developed an invasive fungal infection, either proven or probable, during the studies.
Učinkovitost so merili z opazovanjem, pri koliko bolnikih se je med raziskavami razvila invazivna glivična okužba, dokazana ali verjetna.
The European Commission granted a marketing authorisation valid throughout the European Union, for Posaconazole SP to SP Europe on 25 October 2005.
Evropska komisija je dovoljenje za promet z zdravilom Posaconazole SP, veljavno po vsej Evropski uniji, odobrila družbi SP Europe dne 25. oktobra 2005.
Other common side effects (seen in between 1 and 10 patients in 100) are neutropenia (low white blood cell count), electrolyte imbalance, anorexia (lack of appetite), dizziness, paresthesia (pins and needles), somnolence (sleepiness), vomiting, abdominal (tummy) pain, diarrhoea, dyspepsia (indigestion), dry mouth, flatulence (gas), signs of liver damage in the blood, rash, asthenia (weakness), fatigue (tiredness) and pyrexia (fever).
Drugi pogosti neželeni učinki (o katerih so poročali pri 1 do 10 izmed 100 bolnikov) so nevtropenija (majhno število belih krvnih celic), neravnovesje elektrolitov, anoreksija (pomanjkanje apetita), omotica, parestezija (mravljinčenje), somnolenca (zaspanost), bruhanje, abdominalne bolečine (bolečine v trebuhu), driska, dispepsija (prebavne motnje), suha usta, flatulenca (vetrovi), znaki jetrne okvare v krvi, izpuščaj, astenija (šibkost), utrujenost in pireksija (povišana telesna temperatura).
The oral suspension must be shaken
Pred uporabo je treba peroralno suspenzijo dobro pretresti.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) POSACONAZOLE SP EPAR summary for the public
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) POSACONAZOLE SP Povzetek EPAR za javnost
Caution is also needed when Posaconazole SP is taken at the same time as other medicines.
Prav tako je potrebna previdnost pri sočasnem jemanju zdravila Posaconazole SP z drugimi zdravili.
Without ergosterol, the fungus is killed or prevented from spreading.
Brez ergosterola glivica odmre, oziroma se ne more širiti.
• Simvastatin, lovastatin or atorvastatin (used to lower cholesterol).
• simvastatin, lovastatin ali atorvastatin (ki se uporabljajo za zniževanje holesterola).
Posaconazole SP should not be used in patients who are taking any of the following drugs:
Zdravilo Posaconazole SP se ne sme uporabljati pri bolnikih, ki jemljejo katero koli od naslednjih zdravil:
It is used to treat patients with the following diseases, when they cannot tolerate other antifungal medicines (amphotericin B, itraconazole or fluconazole) or have not improved after at least 7 days of treatment with other antifungal medicines:
Uporablja se za zdravljenje bolnikov z naslednjimi boleznimi, kadar ne prenašajo drugih antimikotikov (amfotericina B, itrakonazola ali flukonazola) ali kadar se stanje pri njih ni izboljšalo po vsaj 7 dneh zdravljenja z drugimi antimikotiki.
Posaconazole SP is used if the disease is severe, or if the patient is immunocompromised (with a weakened immune system).
Zdravilo Posaconazole SP se uporablja, če je bolezen huda ali če je bolnik imunokompromitiran (ima oslabljen imunski sistem).
Other information about Posaconazole SP:
Druge informacije o zdravilu Posaconazole SP:
• chromoblastomycosis and mycetoma (long-term fungal infections of the skin or the tissue just below the skin, usually caused by fungal spores infecting wounds due to thorns or splinters),
• kromoblastomikoza in micetom (dolgotrajni glivični okužbi kože in podkožnega tkiva, ki ju navadno povzročajo glivične spore, ki okužijo rane, ki jih povzročijo trni ali trske),
This can be either because they have cancer in the blood or bone marrow and have received chemotherapy, or because they have had a haematopoietic stem cell transplant (a transplant of cells that make blood cells) and are receiving high doses of immunosuppressant medicines.
Ta je lahko posledica krvnega raka ali raka kostnega mozga in kemoterapije ali presaditve hematopoetskih matičnih celic (presaditev celic, ki proizvajajo krvne celice) in prejemanja velikih odmerkov imunosupresivnih zdravil.
• Pimozide (used for treating mental illness),
• pimozid (ki se uporablja za zdravljenje duševnih bolezni),
The list of fungi against which Posaconazole SP is active can be found in the Summary of Product Characteristics (also part of the EPAR).
Seznam glivic, proti katerim deluje zdravilo Posaconazole SP, je naveden v Povzetku glavnih značilnosti zdravila (tudi del EPAR).
Posaconazole SP also successfully treated 11 of 24 patients who had proven or probable fusariosis, 9 of 11 patients with chromoblastomycosis or mycetoma, and 11 of 16 patients with coccidioidomycosis.
Zdravilo Posaconazole SP je prav tako uspešno pozdravilo 11 od 24 bolnikov, ki so imeli dokazano ali verjetno fuzariozo, 9 od 11 bolnikov s kromoblastomikozo ali micetomom in 11 od 16 bolnikov s kokcidioidomikozo.
• Cisapride (used for stomach problems),
• cisaprid (ki se uporablja za zdravljenje želodčnih težav),
The study included 107 patients with aspergillosis, 18 patients with fusariosis, 11 with chromoblastomycosis or mycotema, and 16 with coccidioidomycosis.
V raziskavo je bilo vključenih 107 bolnikov z aspergilozo, 18 bolnikov s fuzariozo, 11 bolnikov s kromoblastomikozo ali micetomom in 16 s kokcidioidomikozo.
Posaconazole SP is given with a meal or nutritional supplement.
Zdravilo Posaconazole SP se daje s hrano ali prehranskimi dodatki.
In invasive aspergillosis, a successful response at the end of treatment was seen in 42% of the patients taking Posaconazole SP, compared with 26% of the comparison group.
Pri invazivni aspergilozi so uspešen odziv na koncu zdravljenja ugotovili pri 42 % bolnikov, ki so prejemali zdravilo Posaconazole SP, v primerjavi s 26 % bolnikov v primerjalni skupini.
Posaconazole SP is an oral suspension that contains the active substance posaconazole (40 mg/ml).
Zdravilo Posaconazole SP je peroralna suspenzija, ki vsebuje zdravilno učinkovino posakonazol (40 mg/ml).
Posaconazole SP treatment should be started by a doctor who has experience in the management of fungal infections or of treating patients at high risk of invasive fungal infections.
Zdravljenje z zdravilom Posaconazole SP mora začeti zdravnik, ki ima izkušnje pri obravnavi glivičnih okužb ali pri zdravljenju bolnikov z velikim tveganjem za invazivne glivične okužbe.
Posaconazole SP should not be used in people who may be hypersensitive (allergic) to posaconazole or any of the other ingredients.
Zdravilo Posaconazole SP se ne sme uporabljati pri osebah, ki utegnejo biti preobčutljive za (alergične na) posakonazol ali katerokoli drugo sestavino.
• Terfenadine, astemizole (used for allergy),
• terfenadin, astemizol (ki se uporablja za zdravljenje alergij),
The results obtained with Posaconazole SP were compared with the records of 218 patients who were treated with other antifungal medicines.
Rezultate, ki so jih dobili z zdravilom Posaconazole SP, so primerjali s poročili 218 bolnikov, ki so se zdravili z drugimi antimikotiki.
The Committee decided that Posaconazole SP's benefits are greater than its risks for treatment of invasive aspergillosis, fusariosis, coccidioidomycosis, chromoblastomycosis and mycetoma in patients who cannot tolerate other antifungal drugs or have not improved after at least 7 days of treatment.
Odbor je odločil, da so koristi zdravila Posaconazole SP večje od z njim povezanih tveganj pri zdravljenju invazivne aspergiloze, fuzarioze, kokcidioidomikoze, kromoblastomikoze in micetoma pri bolnikih, ki ne prenašajo drugih antimikotikov, ali pri katerih se stanje po 7 dneh zdravljenja ni izboljšalo.
• Halofantrine (used to treat malaria),
• halofantrin (ki se uporablja za zdravljenje malarije),
• invasive aspergillosis (a type of fungal infection due to Aspergillus),
• invazivna aspergiloza (vrsta glivične okužbe, ki jo povzroča Aspergillus),
In the treatment of fungal infections except candidiasis, Posaconazole SP is given at a dose of 400 mg (10 ml) twice a day, or 200 mg (5 ml) four times a day in patients who cannot tolerate a meal.
Za zdravljenje glivičnih okužb, razen kandidioze, se zdravilo Posaconale SP daje v odmerku 400 mg (10 ml) dvakrat dnevno ali 200 mg (5 ml) štirikrat dnevno pri bolnikih, ki ne prenesejo obroka.
In the prevention of invasive fungal infections, the effectiveness of Posaconazole SP has been studied in 600 stem cell transplant patients with fluconazole as a comparator and 602 patients with blood or bone marrow cancer, comparing it to fluconazole or itraconazole.
Glede preprečevanja invazivnih glivičnih okužb so učinkovitost zdravila Posaconazole SP preučevali pri 600 bolnikih, ki so imeli presaditev matičnih celic, pri katerih so ga primerjali s flukonazolom, in 602 bolnikih s krvnim rakom ali rakom kostnega mozga, pri katerih so ga primerjali s flukonazolom in itrakonazolom.
What benefit has Posaconazole SP shown during the studies?
Kakšne koristi je zdravilo Posaconazole SP izkazalo med raziskavami?
• Ergotamine or dihydroergotamine (used to treat migraine),
• ergotamin ali dihidroergotamin (ki se uporablja za zdravljenje migren),
The active substance in Posaconazole SP, posaconazole, is an antifungal medicine that belongs to the triazoles group.
Zdravilna učinkovina zdravila Posaconazole SP, posakonazol, je antimikotik, ki spada v skupino triazolov.
Posaconazole SP was studied in 238 patients with invasive fungal infections that did not respond to standard antifungal treatment.
Zdravilo Posaconazole SP so raziskovali pri 238 bolnikih z invazivnimi glivičnimi okužbami, ki se niso odzivale na standardno antimikotično zdravljenje.
It also decided that Posaconazole SP's effectiveness had been shown as first-line therapy in oropharyngeal candidiasis and in the prophylaxis of invasive fungal infections in patients receiving chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS), and haematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease.
Prav tako je odločil, da je bila dokazana učinkovitost zdravila Posaconazole SP kot zdravljenja prve izbire pri orofaringealni kandidozi in pri preprečevanju invazivnih glivičnih okužb pri bolnikih na kemoterapiji zaradi akutne mieloblastne levkemije (AML) ali mielodisplastičnih sindromov (MDS) in bolnikih, ki so jim presadili hematopoetske matične celice (HSCT) in jih zdravijo z imunosupresivnimi zdravili, da telo ne bi zavrnilo vsadka.
In oropharyngeal candidiasis, Posaconazole SP was as effective as fluconazole.
Pri orofaringealni kandidozi je bilo zdravilo Posaconazole SP enako učinkovito kot flukonazol.
Posaconazole SP can be used to prevent invasive fungal infections in patients whose immune system is weakened.
Zdravilo Posaconazole SP se lahko uporablja za preprečevanje invazivne glivične okužbe pri bolnikih z oslabljenim imunskim sistemom.
• fusariosis (another type of fungal infection due to Fusarium),
• fuzarioza (vrsta glivične okužbe, ki jo povzroča Fusarium),
For candidiasis, Posaconazole SP is given as 200 mg (5 ml) on the first day followed by 100 mg (2.5 ml) once a day for the following 13 days.
Pri kandidiozi je prvi dan odmerek zdravila Posaconazole SP 200 mg (5 ml), potem pa 100 mg (2,5 ml) na dan naslednjih 13 dni.
In the prevention of invasive fungal infections, Posaconazole SP is given as 200 mg (5 ml) three times a day.
Pri preprečevanju invazivnih glivičnih okužb je odmerek zdravila Posaconazole SP 200 mg (5 ml) trikrat dnevno.
What is the risk associated with Posaconazole SP?
Kakšna tveganja so povezana z zdravilom Posaconazole SP?
• coccidioidomycosis (fungal infection of the lungs caused by breathing in spores).
• kokcidioidomikoza (glivična okužba pljuč, ki jo povzroča vdihavanje spor).
Posaconazole SP is also used to treat patients with oropharyngeal candidiasis or ‘thrush', a fungal infection of the mouth and throat due to Candida.
Zdravilo Posaconazole SP se uporablja tudi za zdravljenje bolnikov z orofaringealno kandidiozo, glivično okužbo ust in žrela, ki jo povzroča Candida.
The Committee for Medicinal products for Human Use (CHMP) concluded that, although the main study lacked a control group, the effectiveness of Posaconazole SP in fungal infections refractory to other antifungal medicines had been shown.
Odbor za zdravila za uporabo v humani medicini (CHMP) je odločil, da je bila učinkovitost zdravila Posaconazole SP proti glivičnim okužbam, ki so odporne na druge antimikotike, dokazana kljub odsotnosti kontrolne skupine v glavni raziskavi.
Posaconazole SP has also been studied in 350 HIV-infected patients with oropharyngeal candidiasis, where its effectiveness was compared with that of fluconazole.
Zdravilo Posaconazole SP so preučevali pri 350 bolnikih, okuženih z virusom HIV, ki so imeli orofaringealno kandidiozo in primerjali njegovo učinkovitost s flukonazolom.
In the prevention studies, Posaconazole SP was as effective as fluconazole in stem cell transplant patients, with 5% of patients developing an infection in the Posaconazole SP group, and 9% in the comparator group.
V raziskavah glede preprečevanja je bilo zdravilo Posaconazole SP pri bolnikih s presaditvijo matičnih celic enako uspešno kot flukonazol - v skupini, ki je prejemala zdravilo Posaconazole SP je okužbo razvilo 5 % bolnikov, v primerjalni skupini pa 9 %.
The full EPAR for Posaconazole SP is available here.
Celotno Evropsko javno poročilo o oceni zdravila Posaconazole SP je na voljo tukaj.
Why has Posaconazole SP been approved?
Zakaj je bilo zdravilo Posaconazole SP odobreno?
They recommended that Posaconazole SP be given marketing authorisation.
Odbor je priporočil odobritev dovoljenja za promet z zdravilom Posaconazole SP.
• Quinidine (used for irregular heart beat),
• kinidin (ki se uporablja za zdravljenje motenj srčnega ritma),
Posaconazole SP is an antifungal medicine.
Zdravilo Posaconazole SP je sredstvo proti glivičnim okužbam.
The medicine was more effective than fluconazole or itraconazole in cancer patients, with 2% of patients developing an infection in the Posaconazole SP group, and 8% in the comparator group.
Pri rakavih bolnikih je bilo zdravilo Posaconazole SP učinkovitejše kot flukonazol ali itrakonazol - v skupini, ki je prejemala zdravilo Posaconazole SP, sta okužbo razvila 2 % bolnikov, v primerjalni skupini pa 8 %.
For the full list of all side effects reported with Posaconazole SP, see the Package Leaflet.
Celovit seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Posaconazole SP, najdete v Navodilih za uporabo.
What is Posaconazole SP?
Kaj je zdravilo Posaconazole SP?
What is Posaconazole SP used for?
Za kaj se zdravilo Posaconazole SP uporablja?
How has Posaconazole SP been studied?
Kako je bilo zdravilo Posaconazole SP raziskano?
How is Posaconazole SP used?
Kako se zdravilo Posaconazole SP uporablja?
How does Posaconazole SP work?
Kako zdravilo Posaconazole SP deluje?
Page 2/2©EMEA 2007
Stran 2/2©EMEA 2007
This summary was last updated on 25 September 2007.
Ta povzetek je bil nazadnje posodobljen 25. septembra 2007.
Immunity against infection is usually established after around three days and lasts for up to a year.
Imunost proti okužbi se običajno vzpostavi po približno treh dneh in traja do enega leta.
This makes it suitable for use in a vaccine.
Iz tega razloga je primeren za uporabo v cepivu.
In animals that show more severe signs, treatment with an antibiotic may be necessary.
Pri živalih, ki kažejo resnejše znake, utegne biti potrebno zdravljenje z antibiotikom.
The marketing authorisation was renewed on 25 September 2007.
Dovoljenje za promet z zdravilom je bilo podaljšano 25. septembra 2007.
Cats are vaccinated by giving a 0.2-ml dose into one nostril.
Cepljenje mačk se izvede z dajanjem 0,2 ml odmerka v eno nosnico.
Occasional side effects include sneezing, coughing and a mild and temporary discharge from the eyes or nose.
Občasni neželeni učinki so kihanje, kašljanje ter blag in prehoden izcedek iz oči ali nosu.
The vaccine may be administered by veterinarians only.
Zdravilo lahko dajejo samo veterinarji.
Nobivac Bb is a vaccine.
Zdravilo Nobivac Bb je cepivo.
In case of accidental administration to people seek medical advice immediately and show the Package Leaflet or label to the doctor.
V primeru nenamerne uporabe zdravila pri ljudeh nemudoma poiščite medicinsko pomoč in pokažite zdravniku Navodilo za uporabo ali nalepko.
The effectiveness of Nobivac Bb was investigated in three main studies involving cats of various breeds.
Učinkovitost zdravila Nobivac Bb so preučevali v treh glavnih študijah z mačkami različnih pasem.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Nobivac Bb exceed the risks of its use.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je sklenil, da so koristi zdravila Nobivac BB večje od z njimi povezanih tveganj.
When a cat is given the vaccine, the immune system recognises the bacteria as ‘foreign' and makes a special type of antibodies against them.
Ko mačka prejme cepivo, imunski sistem prepozna bakterije kot tujke in proti njim razvije posebno vrsto protiteles.
Although the risk for people with weak immune systems becoming infected with B. bronchiseptica is extremely low, it is advised that cats which are in close contact with such people are not vaccinated with Nobivac Bb, since they can shed the bacteria intermittently for up to a year after vaccination.
Čeprav je tveganje, da bi se osebe s šibkimi imunskimi sistemi okužile z B. bronchiseptico, izjemno majhno, cepljenje mačk, ki so v tesnem stiku s takimi osebami, z zdravilom Nobivac Bb ni priporočljivo, saj lahko mačke bakterijo izločajo s prekinitvami tudi še eno leto po cepljenju.
Vaccines against B. bronchiseptica that are administered through the nose are also used in dogs.
Cepiva proti B. bronchiseptici, ki se dajejo skozi nos, se uporabljajo tudi pri psih.
Other information about Nobivac Bb:
Druge informacije o zdravilu Nobivac Bb:
The European Commission granted a marketing authorisation valid throughout the European Union for Nobivac Bb to Intervet International B.V. on 10 September 2002.
Evropska Komisija je dovoljenje za promet z zdravilom Nobivac Bb, veljavno po vsej Evropski uniji, odobrila družbi Intervet International B.V.
The main studies showed that Nobivac Bb was effective in reducing the symptoms caused by B. bronchiseptica.
Glavne študije so pokazale, da je bilo zdravilo Nobivac Bb učinkovito pri zmanjševanju simptomov, ki jih povzroča B. bronchiseptica.
The live bacterium strain included in Nobivac Bb differs from other types of B. bronchiseptica because it is missing certain molecules and is therefore less likely to cause disease.
Sev živih bakterij, ki jih vsebuje zdravilo Nobivac Bb, se razlikuje od drugih vrst B. bronchiseptice, ker mu manjkajo določene molekule, zaradi česar je verjetnost, da bi povzročil bolezen, manjša.
What benefit has Nobivac Bb shown during the studies?
Kakšne koristi je zdravilo Nobivac Bb izkazalo med raziskavami?
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) NOBIVAC BB EPAR summary for the public
EMEA/V/C/068 EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) NOBIVAC BB Povzetek EPAR za javnost
In the future, the immune system will be able to produce these antibodies more quickly when it is again exposed to the bacteria.
Ko bo imunski sistem naslednjič izpostavljen bakterijam, bo lahko hitreje izdelal ta protitelesa.
What is the risk associated with Nobivac Bb?
Kakšna tveganja so povezana z zdravilom Nobivac Bb?
Nobivac Bb is used to vaccinate cats aged one month or older against the disease (a flu-like illness) caused by the bacterium B. bronchiseptica.
Zdravilo Nobivac Bb se uporablja za cepljenje mačk, starih en mesec ali več, proti bolezni (gripi podobni bolezni), ki jo povzroča bakterija B. bronchiseptica.
Nobivac Bb is a dry substance and solvent that are made up into a suspension, which is given via the nose.
Zdravilo Nobivac Bb je suha snov in topilo za pripravo suspenzije, ki se daje skozi nos.
Nobivac Bb was the first live B. bronchiseptica vaccine licensed for use in cats.
Zdravilo Nobivac Bb je bilo prvo cepivo z živo B. bronchiseptico, odobreno za uporabo pri mačkah.
Nobivac Bb is a vaccine that contains a live bacterium Bordetella bronchiseptica strain B-C2.
Zdravilo Nobivac Bb je cepivo, ki vsebuje živo bakterijo Bordetella bronchiseptica, sev B-C2.
Why has Nobivac Bb been approved?
Zakaj je bilo zdravilo Nobivac Bb odobreno?
Nobivac Bb contains a type of live B. bronchiseptica called strain B-C2.
Zdravilo Nobivac Bb vsebuje vrsto žive B. bronchiseptice, imenovane sev B-C2.